New drug timing may boost lung cancer treatment
NCT ID NCT04163432
First seen Dec 18, 2025 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study tests whether giving immunotherapy (durvalumab) and chemotherapy at different times works better than the usual schedule for people with advanced non-squamous lung cancer. About 43 adults who have not had these treatments before will be randomly assigned to one of two staggered dosing plans. The goal is to see which schedule provides more benefit and fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.